TransCode Therapeutics In...
(RNAZ)
undefined
undefined%
At close: undefined
3.64
-1.89%
After-hours Jan 03, 2025, 04:00 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 516.75K | 98.61K | 42.47K | n/a | n/a | n/a |
| Gross Profit | -516.75K | -98.61K | -42.47K | n/a | n/a | n/a |
| Operating Income | -19.42M | -18.67M | -6.15M | -726.60K | -456.87K | -384.00K |
| Interest Income | n/a | 20.41K | 664.00 | 136.00 | 34.00 | 68.92K |
| Pretax Income | -18.55M | -17.56M | -6.84M | -2.34M | -607.21K | -453.44K |
| Net Income | -18.55M | -35.13M | -6.94M | -2.74M | -764.14K | -453.44K |
| Selling & General & Admin | 6.64M | 8.43M | 3.40M | 442.14K | 230.56K | 301.46K |
| Research & Development | 12.26M | 10.23M | 2.75M | 284.46K | 226.31K | 82.53K |
| Other Expenses | n/a | -1.08M | -278.33K | n/a | n/a | n/a |
| Operating Expenses | 19.42M | 17.59M | 5.87M | 726.60K | 456.87K | 384.52K |
| Interest Expense | 50.61K | 17.56M | 95.07K | 394.57K | 156.97K | n/a |
| Selling & Marketing Expenses | -7.15B | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 19.42M | 17.59M | 5.87M | 726.60K | 456.87K | 384.52K |
| Income Tax | n/a | 17.56M | 95.07K | 394.44K | 156.93K | -69.44K |
| Shares Outstanding (Basic) | 179.00K | 16.00K | 10.53K | 7.98K | 6.41K | 6.41K |
| Shares Outstanding (Diluted) | 179.01K | 16.22K | 10.53K | 7.98K | 6.41K | 6.41K |
| EPS (Basic) | -103.61 | -2.20K | -658.8 | -343.19 | -119.27 | -70.77 |
| EPS (Diluted) | -103.61 | -2.17K | -658.8 | -343.19 | -119.27 | -70.77 |
| EBITDA | -17.97M | -17.47M | -6.11M | n/a | n/a | -69.44K |
| Depreciation & Amortization | 516.75K | 98.61K | 42.47K | 726.60K | 456.87K | 384.00K |